Disease State: Post-Inflammatory Hyperpigmentation
The development of post-inflammatory hyperpigmentation (PIH) is a final common result that follows many inflammatory skin processes. Once the acute, inciting event is past, PIH may manifest as an independent diagnosis, and be treated similarly regardless of cause. Treatment of PIH remains challenging, with amelioration often being slow and subtle. Sensitive and standardized outcomes are needed to track the evolution, and regression of PIH. In particular, a standardized outcome set is necessary to reliably and precisely compare the benefits and limitations of the many types of treatments, including topical applications and energy devices, that have been employed.
We aim to develop a core outcome set by (1) identifying all current outcomes from a systematic review of literature; (2) involving other stakeholder groups such as other clinicians, and regulators to participate in identifying additional outcomes; (3) conducting Delphi consensus exercises on the identified outcomes; (4) presenting all results from the Delphi exercises during a face-to-face (if possible) consensus meeting to vote and agree upon a core set of outcomes important for PIH research.
Key Project Team Members
Todd V. Cartee
C3 Methods Partner
Murad Alam (email@example.com)
Kang BY, Ibrahim SA, Shokeen D, Schlessinger DI, Kirkham JJ, Schmitt J, Poon E, Maher IA, Sobanko JF, Cartee TV, Alam M. Postinflammatory hyperpigmentation: protocol for development of a core outcome set for clinical trials. Arch Dermatol Res. 2022 May;314(4):357-361 https://pubmed.ncbi.nlm.nih.gov/34019133/
Updated on May 1, 2022